Primary leiomyosarcoma of the pancreas

Hur, Young Hoe; Kim, Ho; Park, Eun Kyu; Seoung, Jin Shick; Kim, Jinwoong; Jeong, Yong Yeon; Lee, Jae Hyuk; Koh, Yang Seok; Kim, Jung Chul; Kim, Hyun Jong; Cho, Chol Kyoon

doi:10.4174/jkss.2011.81.suppl1.s69

Cited by 31 publications

(35 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most malignancies in the pancreas are epithelial originated adenocarcinoma. Gastro-intestinal stromal tumors (GIST) and neurogenic tumors are the most common non epithelial pancreatic tumors (1). Before histological evaluation, differentiating from epithelial carcinoma is not possible (2).…”

Section: Resultsmentioning

confidence: 99%

“…Most pancreatic sarcomas (PS) are diagnosed in autopsy (1). Presenting symptoms are nonspecific and are abdominal pain, mass, epigastric tenderness or even may present as acute pancreatitis (1,2). In order to elucidate the clinical course and behavior and responses to treatment, we searched PubMed for information regarding primary pancreatic sarcoma.…”

Section: Contextmentioning

confidence: 99%

“…Among those who had sarcoma, only one case had pancreas sarcoma. Most pancreatic sarcomas (PS) are diagnosed in autopsy (1). Presenting symptoms are nonspecific and are abdominal pain, mass, epigastric tenderness or even may present as acute pancreatitis (1,2).…”

Section: Contextmentioning

confidence: 99%

See 2 more Smart Citations

Primary Pancreas Sarcoma, Optimal Treatment and Prognostic Factors

Omidvari

Nasrolahi

Kadkhodaei

et al. 2015

Rep Radiother Oncol

View full text Add to dashboard Cite

Context: Sarcoma is a rare human cancer and pancreatic sarcoma is even rarer. Its treatment and clinical history and prognosis are not well described.Evidence Acquisition: In this review, we collected all articles in the English language found in PubMed that were published between January 2000 to August 2015 to draw conclusions. We found 170 articles in total and 124 articles were excluded. The remaining 46 reports and information of 55 patients were collected and analyzed.Results: Mean age was 57.1 ± 16.7 years and male/female ratio was 27/28. The most common presenting symptom was pain. In 31 cases no adjuvant treatment was prescribed. Others received different chemotherapy agents and only two cases received radiotherapy. Mean tumor size was 9.0 ± 6.8 cm (1 -27 cm) and the most common type was leiomyosarcoma (16 patients). Nine patients had carcinosarcoma and six cases had MFH. The most common site of metastasis was liver, 14 patients had liver metastasis at presentation. Median survival was 14 months. One, three and five year overall survival were 78.4, 48.5 and 48.5 percent, respectively. We found no effective clinical factor in survival.Conclusions: Pancreatic sarcoma is a rare disease and an optimal treatment, such as surgery, chemotherapy or radiotherapy is not well defined.Keywords: Pancreas, Sarcoma, Treatment ContextMost pancreatic tumors are epithelial cancers. Adenocarcinoma is the most common malignancy in this organ. Stromal pancreatic tumors are usually GIST or neurogenic cancers. Primary sarcoma of pancreas (PS) are very rare and most be differentiated from gastrointestinal and retroperitoneal sarcoma with extension to pancreas (1). Among 15,000 patients who were referred to our center for treatment over a 10-year period (2003 -2013), 95 cases had sarcoma. Among those who had sarcoma, only one case had pancreas sarcoma. Most pancreatic sarcomas (PS) are diagnosed in autopsy (1). Presenting symptoms are nonspecific and are abdominal pain, mass, epigastric tenderness or even may present as acute pancreatitis (1, 2). In order to elucidate the clinical course and behavior and responses to treatment, we searched PubMed for information regarding primary pancreatic sarcoma. Evidence AcquisitionWe searched PubMed for primary pancreatic sarcomas. Only studies that reported clinical data were included in the study. Review articles (without reporting a new case), animal studies and genetic or radiologic studies were excluded. Keywords in the title were: "sarcoma" or "leiomyosarcoma" or "liposarcoma" or "rhabdomyosarcoma" or "mesenchymal" or "malignant fibrous histiocytomas" AND "pancreas" or "pancreatic". Articles that had no information about a new patient or were published before the year 2000 were excluded. Metastasis to pancreas (non-primary pancreatic tumors) and non-English reports were also exclusion criteria.All clinical data, including age, sex, and disease presentation, type of sarcoma, and completeness of resection, treatment, site of metastasis and survival were collected. Some studies r...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Contextmentioning

confidence: 99%

See 1 more Smart Citation

Primary Pancreas Sarcoma, Optimal Treatment and Prognostic Factors

Omidvari

Nasrolahi

Kadkhodaei

et al. 2015

Rep Radiother Oncol

View full text Add to dashboard Cite

show abstract

“…Some authors believe it has an aggressive course and usually presents in advanced stages (1,8). Shimizu reported a 49-year-old female with pancreas leiomyosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Leiomyosarcoma of Pancreas: A Rare Malignancy

Omidvari

Nasrollahi

Mokhtari

et al. 2016

Rep Radiother Oncol

View full text Add to dashboard Cite

Introduction: Pancreatic leiomyosarcoma is a rare tumor and its clinical course and treatment is not well described. Case Presentation: This paper reports on a 57-year-old male, who presented epigastric pain and had a 12-cm pancreatic tail leiomyosarcoma. He received adjuvant radiotherapy after complete tumor resection. He developed local recurrence 11 months later and received no further treatment. He died after 3 months. Conclusions:The literature search revealed that pancreatic leiomyosarcoma has a variable clinical course and behavior.

show abstract

“…1 Radical resection is still the best treatment option for localised PLM, and patients who underwent curative resection showed better survival than patients who received palliative care. 2 However, one-quarter of patients had metastasis after curative resection and the management of patients with metastatic lesions has not been ascertained. Effective systemic chemotherapies have not been identified.…”

Section: Introductionmentioning

confidence: 99%

Laparoscopic Approach for Pancreatic Leiomyosarcoma with Metachronous Liver Metastasis

Lee

Jang

Hong

et al. 2017

J Minim Invasive Surg

View full text Add to dashboard Cite

Although pancreatic leiomyosarcoma (PLM) is a rare malignant pancreatic cancer, it usually shows aggressive biological features such as invasion to an adjacent organ or distant metastasis at the time of diagnosis. Radical resection is the best treatment modality but effective chemotherapies have not been identified. A 58-year-old female was referred to us complaining of intermittent left upper quadrant abdominal discomfort. Imaging studies revealed a 10-cm mass in the pancreatic tail. The patient underwent laparoscopic distal pancreatectomy with splenectomy, and the pathological findings were consistent with PLM. Imaging studies 14 months after surgery revealed multiple liver metastases. Because the patient was young with a sufficient remnant liver, we performed laparoscopic metastatectomy without any postoperative complications. Patients with PLM need frequent checkups, even after curative resection. The role of laparoscopic resection should be confirmed in the future.

show abstract

Primary leiomyosarcoma of the pancreas

Cited by 31 publications

References 9 publications

Primary Pancreas Sarcoma, Optimal Treatment and Prognostic Factors

Primary Pancreas Sarcoma, Optimal Treatment and Prognostic Factors

Leiomyosarcoma of Pancreas: A Rare Malignancy

Laparoscopic Approach for Pancreatic Leiomyosarcoma with Metachronous Liver Metastasis

Contact Info

Product

Resources

About